HK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira

Stock News09-03 14:18

Shares of KEYMED BIO-B (02162) climbed more than 3% in Hong Kong trading, last up 2.83% at HK$79.95 with turnover reaching HK$70.71 million. The rally follows the company's announcement of an exclusive licensing agreement with multinational pharmaceutical firm Aeira Pte. Ltd.

Under the deal, Keymed will collaborate with Aeira on the registration and commercialization of its self-developed anti-IL-4Rα monoclonal antibody, Dupilumab Injection (brand name: Kangyueda®), across Southeast Asia and Central Asia. Keymed stands to receive upfront payments, milestone payments tied to regulatory approvals in various countries, and commercialization milestone payments. Additionally, the company is entitled to royalties calculated at up to high double-digit percentages of net product sales in the licensed territories.

Aeira will take charge of regulatory filings and commercialization across 18 countries and regions, including 11 Southeast Asian nations (Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Timor-Leste, and Vietnam), 5 Central Asian countries (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan), as well as Hong Kong SAR and Macau SAR. Keymed will continue to handle manufacturing and product supply for Dupilumab Injection on behalf of Aeira.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128255768?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 14:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128255768","market":"fut","top_or_hot":-1,"title":"HK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira","media":"Stock News","content":"<p>Shares of <b>KEYMED BIO-B (02162)</b> climbed more than 3% in Hong Kong trading, last up 2.83% at HK$79.95 with turnover reaching HK$70.71 million. The rally follows the company's announcement of an exclusive licensing agreement with multinational pharmaceutical firm Aeira Pte. Ltd.<br><br>Under the deal, Keymed will collaborate with Aeira on the registration and commercialization of its self-developed anti-IL-4Rα monoclonal antibody, Dupilumab Injection (brand name: Kangyueda®), across Southeast Asia and Central Asia. Keymed stands to receive upfront payments, milestone payments tied to regulatory approvals in various countries, and commercialization milestone payments. Additionally, the company is entitled to royalties calculated at up to high double-digit percentages of net product sales in the licensed territories.<br><br>Aeira will take charge of regulatory filings and commercialization across 18 countries and regions, including 11 Southeast Asian nations (Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Timor-Leste, and Vietnam), 5 Central Asian countries (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan), as well as Hong Kong SAR and Macau SAR. Keymed will continue to handle manufacturing and product supply for Dupilumab Injection on behalf of Aeira.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-03 14:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>KEYMED BIO-B (02162)</b> climbed more than 3% in Hong Kong trading, last up 2.83% at HK$79.95 with turnover reaching HK$70.71 million. The rally follows the company's announcement of an exclusive licensing agreement with multinational pharmaceutical firm Aeira Pte. Ltd.<br><br>Under the deal, Keymed will collaborate with Aeira on the registration and commercialization of its self-developed anti-IL-4Rα monoclonal antibody, Dupilumab Injection (brand name: Kangyueda®), across Southeast Asia and Central Asia. Keymed stands to receive upfront payments, milestone payments tied to regulatory approvals in various countries, and commercialization milestone payments. Additionally, the company is entitled to royalties calculated at up to high double-digit percentages of net product sales in the licensed territories.<br><br>Aeira will take charge of regulatory filings and commercialization across 18 countries and regions, including 11 Southeast Asian nations (Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Timor-Leste, and Vietnam), 5 Central Asian countries (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan), as well as Hong Kong SAR and Macau SAR. Keymed will continue to handle manufacturing and product supply for Dupilumab Injection on behalf of Aeira.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1128255768","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128255768","pubTimestamp":1788416295,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of KEYMED BIO-B (02162) climbed more than 3% in Hong Kong trading, last up 2.83% at HK$79.95 with turnover reaching HK$70.71 million. The rally follows the company's announcement of an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK4585":"ETF&股票定投概念","KCAI":"KraneShares China Alpha Index ETF","BK1161":"生物科技","02162":"康诺亚-B","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1587":"次新股","BK1574":"生物医药B类股"},"translate_title":"港股警报：Keymed Bio 与 Aeira 达成具有里程碑意义的许可协议，股价飙升超过 3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KCAI":1,"VXUS":1,"02162":1},"content_text":"Shares of KEYMED BIO-B (02162) climbed more than 3% in Hong Kong trading, last up 2.83% at HK$79.95 with turnover reaching HK$70.71 million. The rally follows the company's announcement of an exclusive licensing agreement with multinational pharmaceutical firm Aeira Pte. Ltd.Under the deal, Keymed will collaborate with Aeira on the registration and commercialization of its self-developed anti-IL-4Rα monoclonal antibody, Dupilumab Injection (brand name: Kangyueda®), across Southeast Asia and Central Asia. Keymed stands to receive upfront payments, milestone payments tied to regulatory approvals in various countries, and commercialization milestone payments. Additionally, the company is entitled to royalties calculated at up to high double-digit percentages of net product sales in the licensed territories.Aeira will take charge of regulatory filings and commercialization across 18 countries and regions, including 11 Southeast Asian nations (Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Timor-Leste, and Vietnam), 5 Central Asian countries (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan), as well as Hong Kong SAR and Macau SAR. Keymed will continue to handle manufacturing and product supply for Dupilumab Injection on behalf of Aeira.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128255768","isCrawlerRequest":true}